OKT3 and hepatitis C: Defining the risks [2]

Transplantation

Volumn 63, Issue 1, 1997, Pages 171-172

  Rosen, H R ^a   Martin, P ^a   Freeman R B , Jr ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; TACROLIMUS;

CLINICAL TRIAL; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL;

HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MUROMONAB-CD3; RECURRENCE;

EID: 0031024730     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)